Study to Evaluate MET409 Alone or in Combination With Empagliflozin in Patients With Type 2 Diabetes and NASH

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
A randomized, multi-center study evaluating MET409 (50 mg) alone or in combination with empagliflozin (10 mg) for 12 weeks. Assignment to MET409 will be double-blind and placebo-controlled. Empagliflozin will be incorporated into two of the treatment arms in an open-label manner.
Epistemonikos ID: 6a8a9c2c02c1fa89ee10fa329b9db0eb4a4b15f8
First added on: May 08, 2024